Lead Product(s): NTX-001
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Neuraptive's franchise therapeutic product, NTX-001, in the treatment of patients with peripheral nerve injuries.